2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

“The practice-changing findings of VESALIUS-CV have important implications for the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia, as the results were not yet available at the time of final guideline review and approval.”

Dr. Pamela B. MorrisCardiologist, Vice Chair of the Guideline Writing Committee

“The current guideline differentiates between individuals with ASCVD at very high risk and ASCVD not at very high risk based on the combined inclusion criteria for FOURIER and ODYSSEY OUTCOMES. However, the 2026 guideline authors note that the majority of patients in clinical practice who have ASCVD are at very high risk, with prior MACE and additional high-risk features (recommended LDL-C goal of <55 mg/dL).”

“The significant cardiovascular benefits with more intensive lowering of LDL-C to <55 mg/dL in patients without previous MI or stroke in VESALIUS-CV now blur the distinction between ASCVD risk categories when defining a “goal” LDL-C value. Thus, future updates to the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline should include a single pathway of care for all patients with ASCVD... with an optimal LDL-C goal of <55 mg/dL.”